75 related articles for article (PubMed ID: 24106956)
1. Pancreatic atrophy--a new late toxic effect of sorafenib.
Hescot S; Vignaux O; Goldwasser F
N Engl J Med; 2013 Oct; 369(15):1475-6. PubMed ID: 24106956
[No Abstract] [Full Text] [Related]
2. Pancreatic atrophy from sorafenib.
Sullivan S
N Engl J Med; 2014 Jan; 370(2):186. PubMed ID: 24401074
[No Abstract] [Full Text] [Related]
3. Pancreatic atrophy from sorafenib.
Hescot S; Vignaux O; Goldwasser F
N Engl J Med; 2014 Jan; 370(2):186. PubMed ID: 24401073
[No Abstract] [Full Text] [Related]
4. Case of sorafenib-induced thyroid storm.
Haraldsdottir S; Li Q; Villalona-Calero MA; Olencki TE; Kendra K; Ing SW
J Clin Oncol; 2013 Jun; 31(16):e262-4. PubMed ID: 23610115
[No Abstract] [Full Text] [Related]
5. Sorafenib: osteonecrosis of the jaw.
Prescrire Int; 2015 Nov; 24(165):269. PubMed ID: 26688904
[No Abstract] [Full Text] [Related]
6. Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib.
Pichler M; Carriere C; Mazzoleni G; Kluge R; Eisendle K
Clin Exp Dermatol; 2014 Mar; 39(2):232-3. PubMed ID: 24330088
[No Abstract] [Full Text] [Related]
7. Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival.
Prescrire Int; 2016 Feb; 25(168):37. PubMed ID: 27042725
[TBL] [Abstract][Full Text] [Related]
8. Perforating folliculitis-like reaction related to sorafenib.
Eberst E; Rigau V; Pageaux GP; Guillot B; Kluger N
Cutis; 2014 Jan; 93(1):E8-10. PubMed ID: 24505595
[No Abstract] [Full Text] [Related]
9. Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
El Tal AK; Remichofsky CJ; Mehregan DA; Ganger LK
Int J Dermatol; 2013 Dec; 52(12):1538-41. PubMed ID: 23676092
[No Abstract] [Full Text] [Related]
10. Pustular eruption induced by sorafenib in a case of psoriasis vulgaris.
Maki N; Komine M; Takatsuka Y; Maekawa T; Murata S; Ohtsuki M
J Dermatol; 2013 Apr; 40(4):299-300. PubMed ID: 23398293
[No Abstract] [Full Text] [Related]
11. Influence of Sorafenib and Bevacizumab on pancreatic volume - A monocentric CT based analysis.
Phillip V; Zahel T; Bärtl K; Rasch S; Ebert O; Schmid RM; Rummeny E; Algül H
Pancreatology; 2016; 16(4):621-4. PubMed ID: 26968257
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
García-Martín A; López-Ibarra Lozano PJ; Triviño-Ibáñez EM; Escobar-Jiménez F
Endocrinol Nutr; 2013 Mar; 60(3):152-3. PubMed ID: 22565118
[No Abstract] [Full Text] [Related]
13. Hand-foot-skin reaction related to use of the multikinase inhibitor sorafenib and hard orthotics.
Kusari A; Borok J; Han AM; Valderrama AJ; Friedlander SF
Pediatr Dermatol; 2018 Jul; 35(4):e206-e209. PubMed ID: 29766555
[TBL] [Abstract][Full Text] [Related]
14. Heart failure associated with small molecule tyrosine kinase inhibitors.
Imran TF; Shah R; Ha AS; Thomas R; Joseph J
Int J Cardiol; 2016 Mar; 206():110-1. PubMed ID: 26785036
[No Abstract] [Full Text] [Related]
15. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
Park H; Han SH; Kang H; Park K
Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
[No Abstract] [Full Text] [Related]
16. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
Herzog TJ; Scambia G; Kim BG; Lhommé C; Markowska J; Ray-Coquard I; Sehouli J; Colombo N; Shan M; Petrenciuc O; Oza A
Gynecol Oncol; 2013 Jul; 130(1):25-30. PubMed ID: 23591401
[TBL] [Abstract][Full Text] [Related]
17. Refractory hypoglycemia controlled by sorafenib in solitary fibrous tumor.
Le Jeune S; Des Guetz G; Bihan H; Cohen R; Coindre JM; Mourad JJ
J Clin Oncol; 2013 Mar; 31(9):e118-21. PubMed ID: 23341512
[No Abstract] [Full Text] [Related]
18. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A
Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy.
Hung CT; Chiang CP; Wu BY
J Dermatol; 2012 Dec; 39(12):1076-7. PubMed ID: 22724918
[No Abstract] [Full Text] [Related]
20. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
Kashima T; Ohno Y; Tachibana M
Int J Urol; 2012 Nov; 19(11):1041-2. PubMed ID: 22788573
[No Abstract] [Full Text] [Related]
[Next] [New Search]
